Corporate & Investor Presentation

Capital allocation $ in millions 2Q22 Higher priority . Cash and cash equivalents $194 Reinvest for growth Reinvest in product development for high-return organic growth 7% of FY 2021 revenue invested in R&D Debt $680 Net debt $486 Non-GAAP free cash flow $189 Pursue M&A Actively evaluate potential acquisitions Pursue targets aligned with long-term strategic goals and financial objectives Unused borrowing capacity $1,570 NOTE: Values may not calculate due to rounding Support dividends Regular return of cash to shareholders. through dividend at a level that is meaningful and sustained During 2Q22 $63M invested in R&D (7% of revenue) Paid $61M in dividends to shareholders Lower priority 29 2022 ResMed | Corporate & Investor Presentation - updated 27JAN22 Opportunistically repurchase shares • Current program suspended following Opportunistic repurchase of shares acquisitions of MatrixCare and Propeller ResMed

View entire presentation